SLSarah Maria Leiter

Sarah Maria Leiter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Maria Leiter has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis

    by Aditi Vedi, Jamie Trotman, Joao M. L. Dias, Martina Mijuskovic, Sera Choi, Laura Kingham, Rachel A. Moore, Sarah M. Leiter, Rowena Guermech, Amanda Semerene, et al.

    Whole-genome sequencing (WGS) has been shown to improve diagnosis beyond standard-of-care genetic tests and guide precision treatment for childhood cancer. While WGS is now offered for children with suspected cancer in England, clinical workflows typically return results after several weeks whereas clinical decisions are often required within days. Here we evaluate feasibility and efficacy of a rapid WGS (rWGS) research workflow with streamlined bioinformatics to deliver clinical genomic findings (NCT07201038, Active, not recruiting). In 54 children with suspected or confirmed malignancy, rWGS reduces mean end-to-end turnaround time from 42 to 3 days, whilst increase variant detection rate. Whereby rWGS detected 147 of 155 (95%) clinically actionable variants identified in the cohort, standard of care testing detected 138 of 155 (89%) variants. In a subset of 35 patients assessed prospectively, clinicians report that in 17 (49%), rWGS either (i) facilitates faster access to targeted therapy and risk stratification, or (ii) avoids unnecessary investigations and treatment escalation. These findings indicate feasibility and suggest clinical utility of rWGS when deployed as a first line diagnostic test in pediatric oncology.

  • Open Access

    Observation of risk perception, knowledge and behaviour related to covid-19 in heart failure patients enrolled on a telecoaching program

    by Stefanie Rosner, Sarah M. Leiter, Teresa Trenkwalder, Amadea Erben, Patrick Fuchs, Christian Kloss, Wibke Reinhard, Katharina Knoll

    Background: Telemedical interventions have been shown to reduce mortality and morbidity and improve the quality of life of chronic heart failure (CHF) patients. During the Covid-19 pandemic remote coaching gained further importance; however, it is not clear if Covid-19-specific telecoaching has a long-lasting impact on behaviour change. Methods: Patients were pre-existing participants in a combined tele-monitoring and telecoaching programme for CHF. A total of 419 patients were assessed with a standardised questionnaire immediately before and three weeks after a COVID-19-specific telecoaching in April 2020, as well as eight months later. The aim of the study was to observe changes in knowledge and behaviour regarding COVID-19 risk reduction measures, number of medical contacts and self-perceived health risk over time following the telecoaching module. Results: After telecoaching, patients spontaneously recalled significantly more COVID-19-specific risk reduction measures rising from an average of 2.1 items prior to coaching to 2.5 at short- and long-term follow-up ( p = 0.0002). The number of self-reported medical contacts were significantly lower at short-term than at long-term follow-up (30% vs. 42%, p = 0.0060 family doctor, 5% vs. 12%, p = 0.0014 hospital). CHF patients perceived themselves as low risk for a severe COVID-19 infection, and this perception did not change after telecoaching. No difference in social isolation or concern over time were noted. Conclusions: Our longitudinal observational study suggests a possible effect of a single COVID-19-specific telecoaching module on knowledge about the disease and complying with risk reduction measures, which seems to persist over time. These results should be interpreted with caution in the context of increasing public awareness and public health campaigns.

  • Somatic PLCG1 Mutation in a Vascular Tumor of an Infant

    by Grace Heslin, Sarah M. Leiter, Shahab Shahipasand, Anna‐May Long, Michael Gattens, Neil Sebire, Lea Solman, Jamie Trotman, C. Elizabeth Hook, Sam Behjati

  • Open Access

    Clinical Impact of Ultra-Fast Whole Genome Sequencing in Paediatric Haematology-Oncology Practice

    by David Rowitch, Aditi Vedi, Jamie Trotman, Joao Dias, Martina Mijuskovic, Sera Choi, Laura Kingham, A Moore, Sarah Leiter, Rowena Guermech, et al.

    Whole genome sequencing (WGS) improves childhood cancer diagnosis, enabling precision treatment. However, timely clinical decisions are made within days, while WGS clinical reports using current technologies and workflows, can exceed 6 weeks. Here we report an ‘Ultra-fast WGS (UF-WGS)’ workflow, providing rapid and acurate molecular profiling of childhood malignancies. In 54 children with suspected or confirmed cancer, UF-WGS reduced turnaround time from 37 to 3 days. It captured 95% of clinically actionable variants found by conventional methods, and identified 19 additional actionable variants. UF-WGS led to demonstrable improvements in care for 51% of prospective patients, including avoidance of over-medicalisation and support for timely precision therapy. UF-WGS was feasible across diverse tumour types and sample sources, with additional technical advantages in variant detection and workflow simplicity. These findings indicate UF-WGS can significantly improve the management of paediatric haematology/oncology patients, specifically through precision diagnosis, risk stratification and molecularly informed treatment escalation/de-escalation.

  • Open Access

    Patient passports for rare diseases: results of a pilot study

    by Jo Balfour, Vaila Morrison, Lydia Seed, Joseph Clymer, Emma Warnants, Abigail Lampkin, Sarah M. Leiter, Gemma Chandratillake

    For individuals with rare diseases, complex needs requiring multidisciplinary management can cause disjointed healthcare and challenges communicating with healthcare professionals (HCPs). ‘Patient passports’ support communication and healthcare coordination by sharing healthcare information with HCPs, reducing burden on patients/caregivers. Currently, no widely adopted passport addresses the multifaceted needs of patients with rare diseases. This pilot study was a service evaluation of a rare-disease-specific patient passport, co-designed with patients and HCPs. Patients/caregivers completed surveys before (‘pre-passport’) and after (‘post-passport’) using the passport. HCPs were surveyed on their perception of the passport. Of 157 ‘pre-passport’ survey respondents, 96.2% spent considerable time explaining medical needs to new care teams; 65.6% found communicating care needs challenging. Nearly all respondents (99.4%) believed a document presenting relevant healthcare information would be helpful. Among 55 ‘post-passport’ survey respondents, 85.1% used the passport during care interactions; 72.2% found it eased communication with unfamiliar teams, and 64.2% felt more confident communicating their needs. Over half (53.8%) felt the passport helped access needed care, 67.9% found it more useful than existing tools, and 75.9% were highly likely to recommend it to peers. All 31 HCP respondents listed perceived benefits, including improved HCP-patient/caregiver communication; some noted a preference for formal endorsement. By alleviating patient/caregiver-HCP communication challenges, this rare-disease-specific patient passport can enhance healthcare coordination and patient experiences. Participants’ use of the passport during interactions with care teams and likelihood of recommendation to peers support its widespread integration. Further work to assess usability across healthcare settings and to gain formal endorsement is warranted.


  • Open Access

    Real‐world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland

    by Aditi Vedi, Sarah Maria Leiter, Irum Latif Memon, Arunthethy Mahendrayogam, Elsje Van Rijswijk, Urmila Uparkar, Geoff Shenton, Amelie Trinquand, Katherine Clesham, Vanessa McLelland, et al.

    Summary: Acute promyelocytic leukaemia (APL), defined by the t(15;17)(q24;q21) translocation, accounts for 5%–10% of paediatric acute myeloid leukaemia cases. All‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) are key treatments, though ATO access varies. We evaluated treatment, complications and survival in 50 UK paediatric APL patients diagnosed between 2014 and 2021. All patients received ATRA and most received ATO. Event‐free survival was lower in high‐risk patients (85% vs. 100%, p = 0.03), and those not receiving ATO at diagnosis. All relapsed patients could be salvaged with ATO. Addressing ATO availability and consistent funding is crucial to ensure timely treatment and improve outcomes.


  • A diagnosis of Noonan syndrome through routine whole genome sequencing in a child with an intracranial nongerminomatous germ cell tumor

    by Shathar Mahmood, Sarah M. Leiter, Poe Phyu, Claudia Craven, Gail Horan, Jennifer Gains, Mayen Briggs, Esther Blanco, Sam Behjati, James Watkins, et al.


  • Developing a Paired Whole Genome Sequencing Service for Children With Cancer

    by L. Sarkies, P. Thomas, E.A. Edeko, S. Leiter, J. Trotman, R. Armstrong, A. Vedi


  • Open Access

    Benefits for children with suspected cancer from routine whole-genome sequencing

    by Angus Hodder, Sarah M. Leiter, Jonathan Kennedy, Dilys Addy, Munaza Ahmed, Thankamma Ajithkumar, Kieren Allinson, Phil Ancliff, Shivani Bailey, Gemma Barnard, et al.

    Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n = 152 from a hematology center, n = 130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases. Furthermore, WGS faithfully reproduced every standard-of-care molecular test (n = 738) and revealed several previously unknown genomic features of childhood tumors. We show that WGS can be delivered as part of routine clinical care to children with suspected cancer and can change clinical management by delivering unexpected genomic insights. Our experience portrays WGS as a clinically impactful assay for routine practice, providing opportunities for assay consolidation and for delivery of molecularly informed patient care.


  • Implementation of preductal and postductal oxygen saturation screening in babies born in a district general hospital

    by Emma S Reid, Sarah M Leiter, Holly Silverwood, Amy Cunnington, Karen Ranson, Jacqueline Brown, Martina Noone

    Congenital heart defects (CHD) are the most common congenital anomaly and range from asymptomatic to lethal.1 2 Early recognition is critical to prevent postnatal collapse as CHD account for nearly 10% of neonatal deaths.1